Vitamin D receptor antagonists and their use in treating asthma

Details Vitamin D receptor antagonists and their use in treating asthma Vitamin D receptor antagonists and their use in treating asthma

2011-03-29

2011-03-29

Qazi, Sabiha (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

C552S653000

Reexamination Certificate

active

07915242

ABSTRACT:
Various compounds such as those having the formula I and XIV where the variables have the values described herein antagonize the vitamin D receptor and are useful in treating conditions such as asthma and in preparing medicaments for use in antagonizing the vitamin D receptor or treating conditions such as asthma

REFERENCES:
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5536713 (1996-07-01), Deluca et al.
patent: 5585369 (1996-12-01), DeLuca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 5843928 (1998-12-01), Deluca et al.
patent: 5936133 (1999-08-01), Deluca et al.
patent: 5945410 (1999-08-01), DeLuca et al.
patent: 6376480 (2002-04-01), Kirsch et al.
patent: 6537981 (2003-03-01), DeLuca et al.
patent: 6566352 (2003-05-01), DeLuca et al.
patent: 6579861 (2003-06-01), DeLuca et al.
patent: 6627622 (2003-09-01), DeLuca et al.
patent: 6703380 (2004-03-01), Raskov
patent: 2004/0220418 (2004-11-01), DeLuca et al.
patent: 2005/0070511 (2005-03-01), DeLuca et al.
patent: 2008/0261925 (2008-10-01), Clagett-Dame et al.
Fujishima, et al., “Design and synthesis of potent vitamin D receptor antagonists with A-ring modifications: Remarkable effects of 2alpha-methyl introduction on antagonistic activity,” Bioorg. Med. Chem., 2003, vol. 11, pp. 3621-3631.
Baggiolini et al., “Stereocontrolled Total Synthesis of 1α,25-Dihydroxyergocalciferol,”J. Org. Chem., vol. 51, 3098-3108 (1986); published by American Chemical Society.
Casimir, D.A. et al., “cAMP Activates the Expression of Stearoyl-CoA Desaturase Gene 1 during Early Preadipocyte Differentiation,”J. Biol. Chem., 271(47), pp. 29847-29853 (1996); The American Society for Biochemistry and Molecular Biology, Inc.
Chomczynski, P. et al., “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,”Anal. Biochem., 162, pp. 156-159 (1987); Academic Press, Inc.
Cohen, P. et al., “Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss,”Science, 297, pp. 240-243 (2002).
Collins et al., “Normal Functional Characteristics of Cultured Human Promyelocytic Leukemia Cells (HL-60) After Induction of Differentiation by Dimethylsulfoxide”J. Exp. Med., 149, pp. 969-974 (1979).
U.S. Appl. No. 10/613,201, filed Jul. 3, 2003, DeLuca et al.
Dame et al., “Monoclonal Antibodies to the Porcine Intestinal Receptor for 1,25-Dihydroxyvitamin D3:Interaction with Distinct Receptor Domains,”Biochemistry, vol. 25, pp. 4523-4534 (1986); American Chemical Society.
Daniewski, A. R. et al., “A Novel Silylcopper Catalyst for the Reductive Bromination of Hajos Cione. Improved Preparation of a CD Synthon for the Synthesis of Vitamin D,”J. Org. Chem., 66, pp. 626-628 (2001); American Chemical Society.
Fujishima, T. et al., “Design and Synthesis of Potent Vitamin D Receptor Antagonists with A-Ring Modifications: Remarkable Effects of 2α-Methyl Introduction on Antagonistic Activity,”Bioorg. Med. Chem., 11, pp. 3621-3631, (2003); Elsevier Ltd.
Green, H. et al., “An Established Pre-Adipose Cell Line and its Differentiation in Culture,”Cell, 3, pp. 127-133 (1974); MIT.
Hanessian et al., “Total Synthesis of (-)-Reserpine Using the Chiron Approach,”J. Org. Chem., 62, pp. 465-473 (1997); American Chemical Society.
Herdick, M. et al., “Antagonistic Action of a 25-Carboxylic Ester Analogue of 1α,25-Dihydroxyvitamin D3Is Mediated by a Lack of Ligand-induced Vitamin D Receptor Interaction with Coactivators,”J. Biol. Chem., 275, pp. 16506-16512 (2000).
Herdick, M. et al., “Mechanism of the Antagonistic action of a 25-Carboxylic Ester Analogue of 1α,25-Dihydroxyvitamin D3,”Proceedings of the 11thInternational Vitamin D. Workshop, A. W. Norman, R. Bouillon, and M. Thomasset (eds.), pp. 259-262.
Kutner et al., “Novel Convergent Synthesis of Side-Chain-Modified Analogues of 1α,25-Dihydroxycholecalciferol and 1α,25-Dihydroxyergocalciferol,”J. Org. Chem., vol. 53, 3450-3457 (1988); American Chemical Society.
Lythgoe et al., “Calciferol and its Relatives. Part 22. A direct total Synthesis of Vitamin D2and Vitamin D3,”J. Chem. Soc. Perkin Trans. I, pp. 590-595 (1978).
Lythgoe, “Synthetic Approaches to Vitamin D and its Relatives,”Chem. Soc. Rev., vol. 9, 449-475 (1983).
Mackall, J. C. et al., “Induction of Lipogenesis during Differentiation in a ‘Preadipocyte’ Cell Line,”J. Biol. Chem., 251(20), pp. 6462-6464 (1976).
Mandrup, S. et al., “Regulating Adipogenesis,”J. Biol. Chem., 272(9), pp. 5367-5370 (1997); The American Society for Biochemistry and Molecular Biology, Inc.
Mascareñas et al., “Studies on the Synthesis of Side-Chain Hydroxylated Metabolites of Vitamin D. 3. Synthesis of 25-Ketovitamin D3and 25-Hydroxyvitamin D3,”J. Org. Chem., vol. 51, 1269-1272 (1986); American Chemical Society.
Miyamoto et al., “Synthetic Studies of Vitamin D Analogues. XIV. Synthesis and Calcium Regulating Activity of Vitamin D3Analogues Bearing a Hydroxyalkoxy Group at the 2β-Position,”Chem. Pharm. Bull., vol. 41(6), pp. 1111-1113 (1993); Pharmaceutical Society of Japan.
Mincione et al., “Improved Conversion of Vitamin D2into the Windaus Ketone and its Regioselective Hydroxylation via Organoboranes at C26,”Synth. Commun., vol. 19(5&6), pp. 723-735 (1989).
Nishii et al., “The Development of Vitamin D3Analogues for the Treatment of Osteoporosis,”Osteoporosis Int. Suppl., vol. 1, 190-193 (1993); European Foundation for Osteoporosis.
Ntambi, J. M. et al., “Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity,”Proc. Natl. Acad. Sci. USA, 99(17), pp. 11482-11486 (2002).
Okano et al., “Regulatory Activities of 2β-(3-Hydroxypropoxy)-1α, 25-Dihydroxy-Vitamin D3, a Novel Synthetic Vitamin D3Derivative, on Calcium Metabolism,”Biochem. Biophys. Res. Commun., vol. 163(3), 1444-1449 (1989); published by Academic Press, Inc.
Ostrem et al., “24- and 26-homo-1,25-dihydroxyvitamin D3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro,”Proc. Natl. Acad. Sci. USA, vol. 84, pp. 2610-2614 (1987).
Ostrem et al., “Induction of Monocytic Differentiation of HL-60 Cells by 1,25-Dihydroxyvitamin D Analogs,”J. Biol. Chem., vol. 262(29), pp. 14164-14171 (1987); The American Society for Biochemistry and Molecular Biology, Inc.
Peleg, S.,Chapter 60: Molecular Basis for Differential Action of Vitamin D Analogs, In: Vitamin D, Feldman, Glorieux and Pike (eds.), pp. 1011-1025 (1977); Academic Press.
Perlman et al., “1α,25-Dihydroxy-19-Nor-Vitamin D3, A Novel Vitamin D-Related Compound with Potential Therapeutic Activity,”Tetrahedron Lett., vol. 31(13), pp. 1823-1824 (1990); Pergamon Press, Great Britain.
Perlman et al., “Novel Synthesis of 19-Nor-Vitamin D Compounds,”Tetrahedron Lett., vol. 32(52), pp. 7663-7666 (1991); Pergamon Press, Great Britain.
Peterson et al., Studies of the Ketone Obtained from the Ozonolysis of Vitamin D. Molecular Mechanics Calculations for It and Related Hydrindanones,:J. Org. Chem., vol. 51, pp. 1948-1954 (1986); American Chemical Society.
Plum, L. A. et al., “Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl,”Proc. Natl. Acad. Sci. USA, 101(18), pp. 6900-6904 (2004).
Posner et al., Stereocontrolled Total Synthesis of Calcitriol Derivatives: 1,25-Dihydroxy-2(4′-hydroxybutyl)vitamin D3Analogs of an Osteoporosis Drug,J. Org. Chem., vol. 59, pp. 7855-7861 (1994); American Chemical Society.
Posner et al., “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels—Alder Cycloadditions. Preliminary Biologic

Affiliated with

Also associated with

Rating

Vitamin D receptor antagonists and their use in treating asthma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitamin D receptor antagonists and their use in treating asthma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin D receptor antagonists and their use in treating asthma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2712076